A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Phase 3CompletedNCT02888210

Santen Pharmaceutical Co., Ltd.110 enrolled

Overview

To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

110

Conditions

Cataract

Interventions

MD-15 Intraocular LensDEVICE

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who intend to undergo phacoemulsification cataract extraction Exclusion Criteria: * Patients who undergo secondary implantation * Patients with vision loss induced by causes other than cataract * Patients who the principal investigator/subinvestigator considers ineligible for enrollment

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Corrected visual acuity

Time frame: Week 52

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.